Analysis of functional outcome revealed that reduced stroke size in the anti-GPVI treated mice also translated into a better Neuroscore (median with (25% and 75%) percentile: rt-PA: 5.0 (4.0, 5.5); rt-PA + a-GPVI: 5.0 (6.0, 7.0); p < 0.05; Figure 2C). Here, GP6 is linked to stroke disorder.